Chauvin M, Ferrier C, Haberer J P, Spielvogel C, Lebrault C, Levron J C, Duvaldestin P
Département d'Anesthésie, Hôpital Ambroise paré, Boulogne, France.
Anesth Analg. 1989 Jan;68(1):1-4.
The effects of cirrhosis on the elimination kinetics and plasma protein binding of sufentanil were evaluated in 12 anesthetized patients with uncomplicated cirrhosis and these findings were compared with data from age-matched control anesthetized patients with normal hepatic and renal function. Sufentanil 3 micrograms/kg was given intravenously as a bolus injection and venous plasma concentrations were measured at intervals up to 10 hrs. The average (+/- SD) elimination half life was 3.5 +/- 0.9 hrs in controls and did not differ in cirrhotics: 4.1 +/- 0.6 hrs. The plasma clearance did not differ between the two groups: 11.3 +/- 2.5 ml.min-1.kg-1 in controls and 10.8 +/- 4.6 ml.min-1.kg-1 in cirrhotic patients. The sufentanil free fraction was also similar in controls (8.3 +/- 1.5%) and in cirrhotic patients (9.6 +/- 1.8%). These data suggest that sufentanil in a single dose should have a similar duration of action in patients with uncomplicated cirrhosis and in normal patients.
在12例无并发症肝硬化的麻醉患者中评估了肝硬化对舒芬太尼消除动力学和血浆蛋白结合的影响，并将这些结果与年龄匹配、肝肾功能正常的对照麻醉患者的数据进行比较。静脉推注给予舒芬太尼3微克/千克，并在长达10小时的间隔时间测量静脉血浆浓度。对照组的平均（±标准差）消除半衰期为3.5±0.9小时，肝硬化患者无差异：4.1±0.6小时。两组间血浆清除率无差异：对照组为11.3±2.5毫升·分钟⁻¹·千克⁻¹，肝硬化患者为10.8±4.6毫升·分钟⁻¹·千克⁻¹。舒芬太尼的游离分数在对照组（8.3±1.5%）和肝硬化患者（9.6±1.8%）中也相似。这些数据表明，单剂量舒芬太尼在无并发症肝硬化患者和正常患者中的作用持续时间应相似。
